Pharmacokinetic interactions between statins and fibrates

Am J Cardiol. 2005 Nov 7;96(9A):44K-49K; discussion 34K-35K. doi: 10.1016/j.amjcard.2005.08.007. Epub 2005 Oct 21.

Abstract

Concomitant use of a fibrate and a statin may offer a therapeutic advantage to patients with dyslipidemia, especially in patients whose low-density lipoprotein cholesterol is controlled by statins but whose high-density lipoprotein cholesterol or triglycerides, or both, are not within goal. However, concern about drug-drug interactions may preclude optimal use of combination statin-fibrate therapy. This article reviews the pharmacokinetics between statins and fibrates, addressing risks associated with drug-drug interactions and combination therapy.

MeSH terms

  • Area Under Curve
  • Biological Availability
  • Clofibric Acid / administration & dosage
  • Clofibric Acid / pharmacokinetics*
  • Clofibric Acid / therapeutic use
  • Drug Combinations
  • Drug Interactions
  • Dyslipidemias / drug therapy*
  • Dyslipidemias / metabolism
  • Half-Life
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Intestinal Absorption
  • Rhabdomyolysis / chemically induced
  • Risk Factors

Substances

  • Drug Combinations
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Clofibric Acid